Bispecific Approach for Patients with non-small cell Lung Cancer Benefiting from Amivantamab for EGFR-Exon-20-Insertion Mutations

被引：0
|
作者：
Rudesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：214 / 214
页数：1
相关论文
共 50 条
  • [1] Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
    Xie, Yuhao
    Lu, Qisi
    Wang, Jing-Quan
    Bo, Letao
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    [J]. DRUGS OF TODAY, 2022, 58 (08) : 389 - 398
  • [2] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Chon, Katie
    Larkins, Erin
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Aungst, Stephanie
    Wearne, Emily
    Subramaniam, Sriram
    Li, Yangbing
    Liu, Jiang
    Sun, Jielin
    Charlab, Rosane
    Zhao, Hong
    Saritas-Yildirim, Banu
    Bikkavilli, Rama Kamesh
    Ghosh, Soma
    Philip, Reena
    Beaver, Julia A.
    Singh, Harpreet
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
  • [3] Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 3 - 16
  • [4] EGFR exon 20 insertion mutations in non-small cell lung cancer
    Wang, Fenfang
    Li, Chenghui
    Wu, Qihuan
    Lu, Hongyang
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
  • [5] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
  • [6] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    [J]. Signal Transduction and Targeted Therapy, 4
  • [7] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [8] Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
    Sabari, J. K.
    Shu, C. A.
    Park, K.
    Leighl, N.
    Mitchell, P.
    Kim, S.
    Lee, J.
    Kim, D.
    Viteri, S.
    Spira, A.
    Han, J.
    Trigo, J.
    Lee, C. K.
    Lee, K. H.
    Girard, N.
    Yang, T.
    Goto, K.
    Sanborn, R. E.
    Yang, J. C.
    Xie, J.
    Roshak, A.
    Thayu, M.
    Knoblauch, R. E.
    Cho, B. C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S108 - S109
  • [9] Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
    Choi, Dae-Ho
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong -Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2448 - 2459
  • [10] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
    David, Gil-Sierra Manuel
    del Pilar, Briceno-Casado Maria
    Cristina, Moreno-Ramos
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
12345